CTL019 in pediatric and young adult relapsed/refractory acute lymphoblastic leukemia (ALL) patients
The biosimilar regulatory pathway
Comparing the efficacy and safety of CT-P10 to rituximab in advanced stages follicular lymphoma
Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM?
Safety analysis of the BCL-2 inhibitor venetoclax for CLL